FDABridge
← Balik sa blog
Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

FDA Stories #018 β€” A Nigerian Shea Butter Producer Had Two Facilities But Only One Registration

They launched in Saks and Nordstrom. Twelve fragrances. Zero FDA registrations. MoCRA had been in effect for over a year. Nobody in their compliance team knew.

Koponan ng FDABridgeβ€’Ene 1, 2026β€’3 min na mabasa

A luxury perfume house based in Grasse, France, had been selling in the US market through department stores for decades. Fragrances, candles, body care β€” a portfolio of over 40 products. Their US distribution was handled by an American partner who managed retail relationships, marketing, and logistics.

In January 2025, the American partner mentioned during a routine call that they had received an inquiry from a retailer asking whether the brand was MoCRA-compliant. The brand's regulatory team in France had never heard of MoCRA.

What they missed

The Modernization of Cosmetics Regulation Act was signed into law in December 2022. It required cosmetic facility registration and product listing beginning in 2023. The French perfume house had been selling in the US for the entire duration of MoCRA's existence without registering their manufacturing facility or listing any of their products. They had no adverse event reporting system. They had no US Agent designated for cosmetics. They were out of compliance on every MoCRA obligation.

The perfume house's regulatory team was experienced in EU cosmetics regulation β€” CPNP notifications, Responsible Person designation, Product Information Files, Safety Assessments. They knew European rules inside and out. But MoCRA was a US law, and no one in their compliance department was monitoring US regulatory changes.

What we did

We registered their Grasse manufacturing facility with the FDA under MoCRA within one week. We listed all 40+ products through FDA's Cosmetics Direct system β€” each product with its full INCI ingredient list, product category, and responsible person information. We designated ourselves as their US Agent. We established an adverse event intake process that routes consumer complaints from their US distributor to the responsible person in France within the MoCRA-required timeline. Total time from first contact to full compliance: 18 business days.

The lesson

MoCRA is new. Many European cosmetic brands β€” even sophisticated ones with full EU compliance programs β€” do not know it exists. If you sell cosmetics in the United States and you have not registered under MoCRA, you are out of compliance. The law does not have a grace period for brands that were already in the market before it was enacted. Register now. fdabridge.com/cosmetics.

Kailangan mo ng tulong sa susunod?

Kailangan ng tulong sa pagpili ng serbisyo?

Ihambing ang mga serbisyo at piliin ang tamang filing path para sa iyong produkto.

Mas marami pang mabasa

Mga kaugnay na artikulo

Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

Mga simbolo sa paglalaman ng medikal na aparato: Ano ang Dapat Malaman ng mga Pang-aalaga sa Kanlurang Bansa Para sa pagpasok sa Mercado ng US

Abr 28, 2026

Ang pagpapalagay ng medikal na aparato sa Estados Unidos ay nangangailangan ng mga tiyak na simbolo para sa tamang komunikasyon. Dapat maunawaan ng mga dayuhang tagagawa ang mga pamantayan ng simbolo na tinatanggap ng FDA bago mag-export ng mga aparato sa merkado ng Amerika.

Magbasa pa β†’
Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

Pagrehistro ng Medikal na Disposisyon para sa mga dayuhang tagagawa: Isang Gawain sa US Regulatory System

Mar 26, 2026

Ang mga tagagawa ng mga medikal na aparato ng dayuhan ay dapat magrehistro ng kanilang mga establisimento, maglista ng kanilang mga aparato, at depende sa klase ng aparato makakuha ng pag-aalis o pahintulot ng FDA bago i-distribute sa Estados Unidos.

Magbasa pa β†’
Pangunahing Pangunahing Pangunahing Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Pangunahang Panguna

Sampong Tanong Dapat Itanong Bago Mag-upa ng isang Konsultor ng FDA

May 24, 2026

Ang pagpili ng isang tagapagbigay ng serbisyo sa pagsunod sa FDA ay isang resulta ng desisyon. Ang sampung tanong na ito ay tumutulong sa mga dayuhang tagagawa na ihiwalayin ang mga may kakayahan na konsultante mula sa mga magtataguyod ng mga problema na hindi nila maiiwasan.

Magbasa pa β†’